They additionally found that PNPLA3 (a top human GWAS hit) and PCSK9 were important in contributing to liver steatosis and more acutely to HCC and can serve as druggable targets for NAFLD given the disease’s wide spectrum (Figure 1) [110]. This evidence concerns the gene PCSK9 and metabolic dysfunction-associated steatotic liver disease.